Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Rhea-AI Summary

Nuvectis Pharma (NVCT), a biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 37th Annual Roth Conference. The event will take place from March 17th-19th in Dana Point, California, where Ron Bentsur, Chairman and Chief Executive Officer, will engage in a fireside chat discussion.

The conference participation highlights Nuvectis's continued engagement with the investment community and its focus on developing innovative treatments for serious unmet medical needs in cancer therapy.

News Market Reaction – NVCT

+5.99%

+5.99% Session move

In the trading session that priced this news, NVCT gained 5.99%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17^th-19^th in Dana Point, California.

Event	37th Annual Roth Conference
Date	March 17, 2025
Time	2:30 PM Pacific Time
Link	https://event.summitcast.com/view/YsA9Ty4sRyad4m3F6KNZ7x/PL5B4myr3WCu9J7XMPKBt7

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.

Nuvectis Pharma Contact

Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com

Media Relations Contact

Kevin Gardner
LifeSci Advisors
 kgardner@lifesciadvisors.com

FAQ

When and where is Nuvectis Pharma (NVCT) presenting at the Roth Conference 2025?

Nuvectis Pharma will participate in a fireside chat at the 37th Annual Roth Conference from March 17-19, 2025, in Dana Point, California.

What is the focus area of Nuvectis Pharma's (NVCT) drug development pipeline?

Nuvectis Pharma focuses on developing innovative precision medicines for treating serious conditions of unmet medical need in oncology.

Who will represent Nuvectis Pharma (NVCT) at the 2025 Roth Conference?

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis Pharma, will represent the company in a fireside chat.

What type of presentation will NVCT deliver at the 37th Annual Roth Conference?

Nuvectis Pharma will participate in a fireside chat format presentation at the conference.